Effective combinatorial immunotherapy for castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Effective combinatorial immunotherapy for castration-resistant prostate cancer

Published:2017-03-20 Issue:7647 Volume:543 Page:728-732
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Lu Xin,Horner James W.,Paul Erin,Shang Xiaoying,Troncoso Patricia,Deng Pingna,Jiang Shan,Chang Qing,Spring Denise J.,Sharma Padmanee,Zebala John A.,Maeda Dean Y.,Wang Y. Alan,DePinho Ronald A.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature21676.pdf

Reference43 articles.

1. Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Rev. Cancer 15, 701–711 (2015)

2. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015)

3. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014)

4. Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017)

5. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012)

Cited by 433 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in and prospects of immunotherapy for prostate cancer;Cancer Letters;2024-10

2. Siwu decoction suppress myeloid-derived suppressor cells through tumour cells necroptosis to inhibit hepatocellular carcinoma;Phytomedicine;2024-10

3. T cell exhaustion in human cancers;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways;International Immunopharmacology;2024-09

5. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project;Cancers;2024-08-28